Replies to post #43699 on Biotech Values

[DewDiligence]

AGI-1067 vs Placebo:
Time to Onset of Diabetes

[DewDiligence]

> AGIX - My next prediction: UA will have a substantially more neutral trend than Revasc.<

Wouldn’t you expect UA to roughly track non-fatal MI? Doesn’t sound like you’re exactly going out on a limb here :-)

[OTC BB King]

AGIX => what about for diabetes? Those results seemed pretty compelling.

[iwfal]

AGIX - My next prediction:

UA will have a substantially more neutral trend than Revasc.

Last post for the day - this was indeed the outcome. So I think the MOA is pretty solid. And the result was nowhere near a fluke.

BTW - I think diabetes is the immediate path forward. I think there is a moderately good chance for approval based on ARISE alone. But I'll admit I don't have the FDA calibrated here.

Clark